SAB Biotherapeutics, Inc. (SABS)
Nasdaq · Healthcare · Biotechnology
$3.10+4.03%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $282M
- 52-week range
- $2.10 – $5.15
- 52-week change
- +27.35%
- EPS (trailing)
- −$1.29
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- $13.3M
- Diluted EPS
- −$0.79
- Free cash flow
- −$45.7M
From the company’s annual report on SEC EDGAR.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Headquarters: Miami Beach, United States · 86 employees · sab.bio